Get started
Author

Alejandro Martín García-Sancho

Observed names: Alejandro M. Garcia-Sancho, Alejandro Martin Garcia-Sancho, Alejandro Martin García-Sancho, Alejandro Martín García‐Sancho
Institutions: Universidad de Salamanca, Instituto de Salud Carlos III, Complejo Hospitalario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca
Observed institutions: Universidad de Salamanca, Instituto de Salud Carlos III, Hospital de Basurto, Complejo Hospitalario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca
ORCID: 0000-0001-6330-1028
Observed ORCID: 0000-0001-6330-1028
OpenAlex ID: A5148687658
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
2026 · M Lia Palomba, Stephen J Schuster, et al. · The Lancet · 11
High leptin levels independent of body mass index are associated with inflammation and poorer treatment response in patients with diffuse large B-cell lymphoma
2026 · Lourdes Hontecillas-Prieto, Daniel J. García-Domínguez, et al. · Biomedicine & Pharmacotherapy · 3
EORTC-QLQ-C30 and SKINDEX-29 measurement of health-related quality of life in patients with mycosis fungoides and Sézary syndrome: real-world data in Spanish patients (MICADOS study)
2021 · María del Mar Onteniente Gomis, Belén Navarro Matilla, et al. · European Journal of Cancer · 3
Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations ( MIPI53 )
2026 · Miguel Bastos‐Boente, Alejandro Medina‐Herrera, et al. · British Journal of Haematology · 1
Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis
2026 · Fernando Martin-Moro, Miguel Alcoceba, et al. · Modern Pathology · 1
PDF
Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis
2026 · Nicolas Gower, Pierre Feugier, et al. · Blood · 1
Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second‐line setting
2026 · Ángel Serna, Marc Bosch, et al. · British Journal of Haematology · 1
PB3624 Early coagulation abnormalities as markers of disseminated intravascular coagulation and hemostatic complications after CAR-T therapy
2026 · Adolfo Fernández Sánchez, Fernando Lozano Sutil, et al. · Research and Practice in Thrombosis and Haemostasis
Epcoritamab with rituximab and lenalidomide as first-line treatment for follicular lymphoma (EPCORE NHL-2): an open-label, multicentre, phase 1/2 b trial
2026 · Lorenzo Falchi, Joost S P Vermaat, et al. · The Lancet Haematology
POSTER: ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-227: Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL
2026 · Ariel Avilion, Sahar Ansari, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-142: Golcadomide—A Potential First-in-Class Oral CELMoD Combined With Pola-R-CHP in Frontline Aggressive B-Cell Lymphoma: Safety and 12-Month Efficacy
2026 · Muhamad Alhaj Moustafa, Theodoros Vassilakopoulos, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: CT-227: Measurable Residual Disease by Circulating Tumor DNA in Patients With Third-Line or Later Relapsed or Refractory Follicular Lymphoma Treated With Lisocabtagene Maraleucel in TRANSCEND FL
2026 · Ariel Avilion, Sahar Ansari, et al. · Clinical Lymphoma Myeloma & Leukemia
Odronextamab: a bispecific antibody for follicular lymphoma
2026 · Alejandro Martín García-Sancho, Almudena Cabero-Martínez, et al. · Expert Opinion on Investigational Drugs
Real‐world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B‐cell lymphoma: A study from the GELTAMO network
2026 · Mariana Bastos‐Oreiro, Gloria Iacoboni, et al. · HemaSphere
Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL).
2026 · Martin Hutchings, Andrew David Zelenetz, et al. · Journal of Clinical Oncology
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, + Pola-RCHP in patients (pts) with newly diagnosed aggressive B-cell lymphoma (a-BCL): Safety and 12-month (mo) efficacy results.
2026 · Marc S. Hoffmann, Grzegorz S. Nowakowski, et al. · Journal of Clinical Oncology
Measurable residual disease (MRD) by circulating tumor (ct) DNA in patients (pt) with R/R follicular lymphoma (FL) treated with lisocabtagene maraleucel (liso-cel) in TRANSCEND FL.
2026 · Ariel Avilion, Sahar Ansari, et al. · Journal of Clinical Oncology
Indirect Treatment Comparisons of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in Third-Line or Later Relapsed or Refractory Follicular Lymphoma
2026 · Alexander P. Boardman, Juan Luis Reguera Ortega, et al. · Advances in Therapy
Varnimcabtagene autoleucel (ARI‐0001) in relapsed or refractory mantle cell lymphoma
2026 · Nil Albiol, Nuria Martínez‐Cibrián, et al. · HemaSphere
Comparative outcomes of lisocabtagene maraleucel versus an external control arm in third-line or later relapsed or refractory follicular lymphoma
2026 · Loretta Jo Nastoupil, Alejandro Martín García-Sancho, et al. · Leukemia & lymphoma/Leukemia and lymphoma
PDF
Abstract CT268: Phase 1 study of ARV-393, a PROTAC BCL6 degrader, as monotherapy in patients with advanced non-Hodgkin lymphoma (NHL) or combined with glofitamab in patients with diffuse large B-cell lymphoma (DLBCL)
2026 · Martin Hutchings, Andrew Zelenetz, et al. · Cancer Research
Reply
2026 · Alba Torres-Valle, Jana Neirinck, et al. · Journal of Allergy and Clinical Immunology
PDF
Phase II Interim Results for Rapcabtagene Autoleucel (YTB323) in Patients with First-Line, High-Risk Large B-cell Lymphoma
2026 · Jason Westin, Julio C. Chavez, et al. · Transplantation and Cellular Therapy
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients with Third-Line or Later (3L+) Follicular Lymphoma (FL) from TRANSCEND FL
2026 · Sairah Ahmed, Alejandro Martin García-Sancho, et al. · Transplantation and Cellular Therapy
Works count: 25
Citation count: 21
H-index: 3
I10-index: 1
Year
Topic
Type